Fulgent Genetics, Inc. (FLGT) Misses Q2 EPS by 26c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Fulgent Genetics, Inc. (FLGT) Enters Collaboration with Helio Health for Early Cancer Detection Tests
August 9, 2021 4:04 PM EDTFulgent Genetics, Inc. (NASDAQ: FLGT) and Helio Health announced the companies have entered into a strategic partnership to commercialize Helios blood-based early cancer detection tests. In conjunction with the commercial strategic partnership whereby the company has secured exclusive commercial rights for laboratory develop tests (LDTs) in the U.S. and Canada, Fulgent has made a strategic investment in Helio.
Under this partnership, the companies will initially commercialize and co-brand HelioLiver, a cell-free DNA (cfDNA) methylation blood test that incorporates protein markers and demographics for the detection of hepatocellular carcinoma (HCC) or liver cancer.... More
Fulgent Genetics, Inc. (FLGT) to Acquire CSI Laboratories
August 9, 2021 4:03 PM EDTFulgent Genetics, Inc. (NASDAQ: FLGT) announced that it has acquired CSI Laboratories to expand its presence in somatic molecular diagnostics and cancer testing.
CSI was founded in 1997 to provide a client- and patient-focused model of cancer diagnostic testing for pathologists, community hospitals, and their patients. CSI offers more than 400 unique tests with a focus on oncology and capabilities across flow cytometry, cytogenetic analysis, fluorescence in-situ hybridization (FISH), immunohistochemistry, and molecular genetics. CSIs philosophy of providing expert diagnostic testing with speed, precision, and care, is highly complementary with Fulgents core value... More
